Search

Background: Patients with metastatic gastric cancer (mGC) endure a significant symptom burden following subsequent lines of therapy. Accurate survival estimation is crucial for healthcare professionals and patients to make informed decisions regarding therapy options. This study evaluates Chuang's Prognostic Scale (CPS) for predicting survival in mGC patients after receiving at least two lines of palliative systemic therapy (PST). Method: This prospective study involved 202 patients with mGC. The CPS includes eight categories: cognitive impairment, performance status, weight loss, tiredness, edema, and ascites, with a scoring range from 0 to 8.5. A higher score indicates a poorer prognosis. Results: After a median follow-up period of 3.35 months, the median CPS value was 4.2. 99 patients had a CPS < 4.2, with a median overall survival (mOS) of 5.86 months, while 103 patients with a CPS ≥ 4.2 had an mOS of 3.96 months (P < 0.001). According to the receiver-operating curve, the cut-off value for CPS was ≤ 4.7, with a disease prevalence of 76.7% and an area under the curve of 0.949 (P < 0.0001). The sensitivity was 82.6%, specificity was 97.87%, positive predictive value was 99.2%, and negative predictive value was 63%. Cox regression analysis revealed that CPS was statistically significantly associated with mOS (P < 0.001). Furthermore, CPS was statistically significantly correlated with metastases to the liver, lung, lymph nodes, and bone (P values were 0.03, 0.02, <0.001, and <0.001, respectively). Conclusion: CPS is a valuable and accessible tool that can assist in selecting appropriate therapy for patients with mGC after two lines of PST. [ABSTRACT FROM AUTHOR]

Endometrial cancer (EC) is a complex disease with various subtypes. Although it is considered a treatable disease due to early diagnosis and symptoms, the advanced stage, which represents approximately 8% of cases, is associated with poor outcomes, reflecting the absence of efficient systemic therapy. There are various molecular classifications available and many pathways involved in EC pathogenesis. Advances in understanding its biology have led to the development of a classification system to help tailor treatment strategies depending on both patients and disease features. Currently, immunotherapy and targeted therapies are key treatments for EC, whether recurrent or advanced. In this review, we aim to summarize the molecular classification of EC briefly and its impact on treatment strategies, as well as the proposed targeted therapy. The data collection is based on searches on scientific websites, clinical trials (ClinicalTrials.gov), and international guidelines from Europe's leading medical oncology society (ESMO) and the National Comprehensive Cancer Network (NCCN). [ABSTRACT FROM AUTHOR]

Background: The ototoxicity of both chemotherapy and radiotherapy has been studied. Little is known regarding their impact on the vestibular system, particularly, the laboratory vestibular testing that evaluates the effects of both chemotherapy and radiotherapy on the peripheral and central vestibular system. Consequently, the current research was designed to study Videonystagmography (VNG) and video head impulse test (vHIT)in patients with head and neck cancer receiving chemotherapy and radiotherapy for early diagnosis of vestibularsystem abnormalities. Methods: This study included two groups with head and neck cancer: group I included 19 patients receiving chemotherapy and group II included 19 patients receiving radiotherapy. Basic audiological evaluation, VNG, and vHIT were conducted on all patients before treatment and 3 months following treatment. Results: Regarding pure tone audiometry, there was a statistically significant increase in hearing threshold at high frequencies in patients receiving chemotherapy and radiotherapy before and after treatment. As regards the VNG test, there was a statistically significant impairment in saccade, smooth pursuit, optokinetic, and caloric tests in patients before and after receiving chemotherapy. However, in patients receiving radiotherapy, there was no statistically significant difference in the VNG test battery except for increased value of caloric weakness. vHIT abnormalities were reported in patients of both groups. Conclusions: This study demonstrated the ototoxic and vestibulotoxic effects of both chemotherapy and radiotherapy in patients with head and neck cancer. [ABSTRACT FROM AUTHOR]